Papers/PMID:33045675
A pilot study of the effects of chromium picolinate supplementation on serum fetuin-A, metabolic and inflammatory factors in patients with nonalcoholic fatty liver disease: A double-blind, placebo-controlled trial.
Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS)2021The record
4 findings · 1 compound · 4 endpoints
What it reported
How to read these marksWhat moved
4 findings
chromium(3+) — decreases interleukin-6 concentration
Evidence strength: very limited.Finding“Chromium reduced triglyceride (TG), atherogenic index of plasma (AIP), very-low-density lipoprotein (VLDL), insulin, homeostatic model assessment for insulin resistance (HOMA-IR), high-sensitivity C-reactive protein (hs-CRP), interleukin (IL) -6, tumor necrosis factor-alpha (TNF-α) and fetuin-A significantly compared to placebo group (p < 0.05).”
Quoted verbatim from A pilot study of the effects of chromium picolinate supplementation on serum fetuin-A, metabolic and inflammatory factors in patients with nonalcoholic fatty liver disease: A double-blind, placebo-controlled trial.. - Study
- RCT
- Dose
- chromium picolinate 400 mcg/day for 3 months
- Population
- 46 patients with nonalcoholic fatty liver disease
A pilot study of the effects of chromium picolinate supplementation on serum fetuin-A, metabolic and inflammatory factors in patients with nonalcoholic fatty liver disease: A double-blind, placebo-controlled trial.2021PMID:3304567510.1016/j.jtemb.2020.126659Permalink
chromium(3+) — decreases tumour necrosis factor alpha concentration
Evidence strength: very limited.Findingreplicated ×1“Chromium reduced triglyceride (TG), atherogenic index of plasma (AIP), very-low-density lipoprotein (VLDL), insulin, homeostatic model assessment for insulin resistance (HOMA-IR), high-sensitivity C-reactive protein (hs-CRP), interleukin (IL) -6, tumor necrosis factor-alpha (TNF-α) and fetuin-A significantly compared to placebo group (p < 0.05).”
Quoted verbatim from A pilot study of the effects of chromium picolinate supplementation on serum fetuin-A, metabolic and inflammatory factors in patients with nonalcoholic fatty liver disease: A double-blind, placebo-controlled trial.. - Study
- RCT
- Dose
- chromium picolinate 400 mcg/day for 3 months
- Population
- 46 patients with nonalcoholic fatty liver disease
A pilot study of the effects of chromium picolinate supplementation on serum fetuin-A, metabolic and inflammatory factors in patients with nonalcoholic fatty liver disease: A double-blind, placebo-controlled trial.2021PMID:3304567510.1016/j.jtemb.2020.126659Permalink
chromium(3+) — decreases HOMA-IR
Evidence strength: very limited.Findingreplicated ×2“Chromium reduced triglyceride (TG), atherogenic index of plasma (AIP), very-low-density lipoprotein (VLDL), insulin, homeostatic model assessment for insulin resistance (HOMA-IR), high-sensitivity C-reactive protein (hs-CRP), interleukin (IL) -6, tumor necrosis factor-alpha (TNF-α) and fetuin-A significantly compared to placebo group (p < 0.05).”
Quoted verbatim from A pilot study of the effects of chromium picolinate supplementation on serum fetuin-A, metabolic and inflammatory factors in patients with nonalcoholic fatty liver disease: A double-blind, placebo-controlled trial.. - Study
- RCT
- Dose
- chromium picolinate 400 mcg/day for 3 months
- Population
- 46 patients with nonalcoholic fatty liver disease
A pilot study of the effects of chromium picolinate supplementation on serum fetuin-A, metabolic and inflammatory factors in patients with nonalcoholic fatty liver disease: A double-blind, placebo-controlled trial.2021PMID:3304567510.1016/j.jtemb.2020.126659Permalink
chromium(3+) — decreases C-reactive protein concentration
Evidence strength: very limited.Findingreplicated ×3“Chromium reduced triglyceride (TG), atherogenic index of plasma (AIP), very-low-density lipoprotein (VLDL), insulin, homeostatic model assessment for insulin resistance (HOMA-IR), high-sensitivity C-reactive protein (hs-CRP), interleukin (IL) -6, tumor necrosis factor-alpha (TNF-α) and fetuin-A significantly compared to placebo group (p < 0.05).”
Quoted verbatim from A pilot study of the effects of chromium picolinate supplementation on serum fetuin-A, metabolic and inflammatory factors in patients with nonalcoholic fatty liver disease: A double-blind, placebo-controlled trial.. - Study
- RCT
- Dose
- chromium picolinate 400 mcg/day for 3 months
- Population
- 46 patients with nonalcoholic fatty liver disease
A pilot study of the effects of chromium picolinate supplementation on serum fetuin-A, metabolic and inflammatory factors in patients with nonalcoholic fatty liver disease: A double-blind, placebo-controlled trial.2021PMID:3304567510.1016/j.jtemb.2020.126659Permalink